Himanshu Batra, Senior Resident Doctor at SMS Hospital Jaipur, shared a post on X:
“Lung cancer at ASCO 2026 was not just about new drugs. It was about a new direction:
- ADCs entering 1L NSCLC.
- Bispecifics challenging old standards.
- Targeted therapy going deeper and longer.
- SCLC finally seeing meaningful new options.
The future of lung cancer care is biomarker-led, not one-size-fits-all.”
